Literature DB >> 30068728

Binding Characteristics of Two Oxytocin Variants and Vasopressin at Oxytocin Receptors from Four Primate Species with Different Social Behavior Patterns.

Jack H Taylor1, Nancy A Schulte2, Jeffrey A French2, Myron L Toews1.   

Abstract

A clade of New World monkeys (NWMs) exhibits considerable diversity in both oxytocin (OT) ligand and oxytocin receptor (OTR) structure. Most notable is the variant Pro8-OT, with proline instead of leucine at the eighth position, resulting in a rigid bend in the peptide backbone. A higher proportion of species that express Pro8-OT also engage in biparental care and social monogamy. When marmosets (genus Callithrix), a biparental and monogamous Pro8-OT NWM species, are administered the ancestral Leu8-OT, there is no change in social behavior compared with saline treatment. However, when Pro8-OT is administered, marmosets' sociosexual and prosocial behaviors are altered. The studies here tested the hypothesis that OTR binding affinities and OT-induced intracellular Ca2+ potencies would favor the native OT ligand in OTRs from four primate species, each representing a unique combination of ancestral lineage, breeding system, and native OT ligand: humans (Leu8-OT, monogamous, apes), macaques (Leu8-OT, nonmonogamous, Old World monkey), marmosets (Pro8-OT, monogamous, NWM), and titi monkeys (Leu8-OT, monogamous, NWM). OTRs were expressed in immortalized Chinese hamster ovary cells and tested for intact-cell binding affinities for Pro8-OT, Leu8-OT, and arginine vasopressin (AVP), as well as intracellular Ca2+ signaling after stimulation with Pro8-OT, Leu8-OT, and AVP. Contrary to our hypothesis, Pro8-OT bound at modestly higher affinities and stimulated calcium signaling at modestly higher potencies compared with Leu8-OT in all four primate OTRs. Thus, differences downstream from a ligand-receptor binding event are more likely to explain the different behavioral responses to these two ligands.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30068728      PMCID: PMC7250472          DOI: 10.1124/jpet.118.250852

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

Review 1.  The oxytocin receptor system: structure, function, and regulation.

Authors:  G Gimpl; F Fahrenholz
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Do marmosets care to share? Oxytocin treatment reduces prosocial behavior toward strangers.

Authors:  Aaryn C Mustoe; Jon Cavanaugh; April M Harnisch; Breanna E Thompson; Jeffrey A French
Journal:  Horm Behav       Date:  2015-04-28       Impact factor: 3.587

3.  Oxytocin and vasopressin enhance responsiveness to infant stimuli in adult marmosets.

Authors:  Jack H Taylor; Jeffrey A French
Journal:  Horm Behav       Date:  2015-10-22       Impact factor: 3.587

Review 4.  Synthetic analogs of oxytocin and the vasopressins.

Authors:  W H Sawyer; M Manning
Journal:  Annu Rev Pharmacol       Date:  1973       Impact factor: 13.820

5.  Intranasal vasopressin affects pair bonding and peripheral gene expression in male Callicebus cupreus.

Authors:  M R Jarcho; S P Mendoza; W A Mason; X Yang; K L Bales
Journal:  Genes Brain Behav       Date:  2011-01-24       Impact factor: 3.449

6.  The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.

Authors:  W Y Chan; N C Wo; M Manning
Journal:  Am J Obstet Gynecol       Date:  1996-11       Impact factor: 8.661

7.  Oxytocin facilitates fidelity in well-established marmoset pairs by reducing sociosexual behavior toward opposite-sex strangers.

Authors:  Jon Cavanaugh; Aaryn C Mustoe; Jack H Taylor; Jeffrey A French
Journal:  Psychoneuroendocrinology       Date:  2014-07-03       Impact factor: 4.905

8.  Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.

Authors:  Markus Muttenthaler; Åsa Andersson; Irina Vetter; Rohit Menon; Marta Busnelli; Lotten Ragnarsson; Christian Bergmayr; Sarah Arrowsmith; Jennifer R Deuis; Han Sheng Chiu; Nathan J Palpant; Margaret O'Brien; Terry J Smith; Susan Wray; Inga D Neumann; Christian W Gruber; Richard J Lewis; Paul F Alewood
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

9.  Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors.

Authors:  Marta Busnelli; Elisabetta Bulgheroni; Maurice Manning; Gunnar Kleinau; Bice Chini
Journal:  J Pharmacol Exp Ther       Date:  2013-05-30       Impact factor: 4.030

Review 10.  Insights into the molecular evolution of oxytocin receptor ligand binding.

Authors:  Johannes Koehbach; Thomas Stockner; Christian Bergmayr; Markus Muttenthaler; Christian W Gruber
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

View more
  4 in total

1.  Binding affinities of oxytocin, vasopressin and Manning compound at oxytocin and V1a receptors in male Syrian hamster brains.

Authors:  Jack H Taylor; Katharine E McCann; Amy P Ross; H Elliott Albers
Journal:  J Neuroendocrinol       Date:  2020-07-14       Impact factor: 3.627

2.  Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.

Authors:  Marsha L Pierce; Jeffrey A French; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2020-03-04       Impact factor: 6.529

3.  Comparison of the pharmacologic profiles of arginine vasopressin and oxytocin analogs at marmoset, titi monkey, macaque, and human oxytocin receptors.

Authors:  Marsha L Pierce; Jeffrey A French; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2020-02-01       Impact factor: 6.529

4.  Leu8 and Pro8 oxytocin agonism differs across human, macaque, and marmoset vasopressin 1a receptors.

Authors:  Aaryn Mustoe; Nancy A Schulte; Jack H Taylor; Jeffrey A French; Myron L Toews
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.